BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with a curative potential for myelodysplastic syndrome (MDS) patients. Allo-HSCT has substantial risks, particularly in the elderly, and its role for older MDS patients has yet to be defined. METHODS: We analyzed 88 MDS patients aged 60 years with allo-HSCT after reduced intensity conditioning regimens over the last decade. The study cohort had high risk features; 47 of 88 (53.4%) patients were > 65 years of age, 24 (27%) patients had cytogenetic abnormalities consistent with monosomal karyotype (MKpos), 33 (38%) patients had histological subtype of RAEB-1 and RAEB-2 at diagnosis, and 45 (51%) patients had a hematopoietic cell transplantation-comorbidity index (HCT-CI) of 3. RESULTS: The 3-year incidence of progression, transplant-related mortality (TRM), and overall survival (OS) were 26% (95% confidence interval [CI], 18%-37%), 35% (95% CI, 26%-47%), and 41% (95% CI, 30%-52%), respectively. MKpos was the only prognostic factor that increased the risk of disease progression compared with good-risk cytogenetics (hazard ratio [HR] 5 9.5, P 5.003) as well as MKneg (HR 5 3.3, P 5.01). For TRM, HCT-CI 3, but not age >65 years, was associated with worse outcomes (HR 5 3.1, P 5.007). Cytogenetics and HCT-CI enabled us to identify prognostic groups for OS. MKpos patients had the worst 3-year OS (17%), whereas patients with good-risk cytogenetics and HCT-CI < 3 had the best OS (92%). CONCLUSION: Our results confirm that allo-HSCT can provide long-term survival in older MDS patients. Cytogenetics and HCT-CI identify prognostic risk groups and guide selection of older MDS patients who are candidates for allo-HSCT.
INTRODUCTION
Myelodysplastic syndromes (MDSs) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, dysplastic morphologic features, pancytopenia, and a risk of transformation acute myeloid leukemia (AML).
1,2 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for MDS. The role and tolerability of allo-HSCT with the use of myeloablative regimens in younger MDS patients is well established. 3, 4 Allogeneic HSCT is a complex procedure with a substantial risk of morbidity and transplant-related mortality (TRM), particularly in the elderly. 5, 6 More than 80% of MDS patients are >60 years of age at diagnosis. 7 The introduction of reduced intensity conditioning (RIC) regimens has extended the availability of allo-HSCT into older and frailer MDS patients. 8 Two large registry analyses indicated that older age alone was not a poor prognostic factor for TRM or survival in MDS patients after allo-HSCT. 9, 10 However, the reported registry studies confirming the feasibility of allo-HSCT in older patients included not only MDS but also AML patients treated with both myeloablative and reduced intensity conditioning regimens. In those cohorts, the median age was <60 years and transplantations were performed before 2006.
Selection of candidates for allogeneic HSCT among older MDS patients is a complex decision process. Disease and patient characteristics-including disease status at transplantation, cytogenetic findings, comorbidities and donor typesneed to be considered to assess the risks and potential benefits. We analyzed the patient and disease characteristics predictive of treatment outcomes in MDS patients aged 60 years who underwent transplantation with RIC regimens at our institution after 2005.
PATIENTS AND METHODS

Patient Population
We retrospectively analyzed 88 consecutive MDS patients 60 years of age who underwent their first allo-HSCT at MD Anderson Cancer Center between September 2005 and July 2015.
The diagnosis of MDS was made according to World Health Organization criteria, 11 and the following MDS categories were considered: refractory anemia (RA; n 5 2, 2.3%); RA with ringed sideroblasts (n 5 2, 2.3%); refractory cytopenia with multilineage dysplasia (RCMD; n 5 10, 11.4%); RCMD and ringed sideroblasts (n 5 1, 1.1%); MDS associated with isolated del(5q) (n 5 1, 1.1%); RA with excess blast-1 (RAEB-1; n 5 15, 17%); RA with excess blast-2 (RAEB-2; n 5 18, 20.4%); chronic myelomonocytic leukemia-1 (CMML-1; n 5 10, 11.4%); and chronic myelomonocytic leukemia-2 (CMML-2; n 5 4, 4.6%). The histological subtype was MDS-unclassifiable (MDS-U) in 25 (28.4%) patients. Patients with 20% bone marrow blasts at any time point during their disease course were classified to have AML and excluded from these analyses.
Disease Characteristics
All bone marrow samples were analyzed by standard cytogenetic techniques. An abnormality was considered clonal and thus mentioned in the karyotype when at least 2 metaphases had the same aberration in cases of a structural abnormality or an extra chromosome, in accordance with the International System for Human Cytogenetic Nomenclature. Any monosomy had to be present in at least 3 metaphases. Cytogenetic abnormalities were categorized according to the revised International Prognostic Scoring System (IPSS-R) and monosomal karyotype (MK). 12 Monosomal karyotype was defined as the presence of 2 distinct autosomal chromosome monosomies or 1 single autosomal monosomy in combination with structural abnormalities. 13 Patients with normal cytogenetics or with isolated del(5q), del(12p), or del(20q) were categorized as good-risk cytogenetics. 14 IPSS-R for MDS that defines 5 risk groups with different clinical outcomes were calculated according to Greenberg et al. 15 The hematopoietic cell transplantationcomorbidity index (HCT-CI) 16 was used to assess the comorbidity status at the time of transplantation.
Stem Cell Source, HLA Typing, and Donors Hematopoietic stem cell source was peripheral blood in 55 (63%) and bone marrow in 33 (37%) patients. All donors had high-resolution molecular typing of class 1 and 2 antigens. Of 88 patients, 48 (55%) had matched related donors, 30 (34%) had matched unrelated donors, and 10 (11%) had haploidentical donors. Haploidentical donor recipients were included in the analyses based on recent data showing similar outcomes of haploidentical transplants compared with matched donor if performed with the use of posttransplantation cycloposhamide. 17, 18 Our results were similar to published data with comparable outcomes between haploidentical and matched donors. Moreover, analyses remained similar when haploidentical donor recipients were excluded, supporting the notion that including haploidentical patients was not misleading our analyses (Supporting Tables 1 and 2 ). Mismatched unrelated donor recipients including cord blood units were excluded from this analyses.
Conditioning Regimens and Graft-Versus-Host Disease
There were 2 RIC regimens used over the study period at the discretion of the treating physician: 1) intravenous busulfan in a dose calculated to target an average daily sys- The graft-versus-host disease (GVHD) prophylaxis in matched related donor and matched unrelated donor recipients was tacrolimus and methotrexate. Matched unrelated donor recipients were also treated with rabbit antithymocyte globulin (thymoglobulin, Genzyme) given as 0.5 mg/kg on day 4, 1 mg/kg on day 3, and 2 mg/kg on day 2. Patients with haploidentical-related transplants received 50 mg/kg cyclophosphamide on days 13 and 14 and tacrolimus and mycophenolate mofetil starting on day 15 as described previuosly. 19 Patients received mycophenolate mofetil at a dose of 15 mg/kg 3 times daily (maximum, 1000 mg per dose), which was continued until day 1100 and then tapered.
Treatment protocols and this study were approved by the University of Texas MD Anderson Cancer Center Institutional Review Board, and all patients provided written informed consent.
Endpoints and Definitions
The primary endpoints were the cumulative incidence of disease progression, TRM, and overall survival (OS). OS was defined as the time between transplantation and death (from any cause) or last follow-up. For TRM, any death in the absence of disease progression was considered an event, and disease progression was a competing event.
Acute GVHD was evaluated by the standard clinical criteria derived from organ staging, 20 modified to include upper gastrointestinal acute GVHD per the GVHD consensus conference. 21 Chronic GVHD was classified according to National Institutes of Health guidelines. 22 
Statistical Methods
Actuarial OS was estimated using the Kaplan-Meier method. The cumulative incidence of disease progression and TRM was estimated using the cumulative incidence method to account for competing risks.
Death of any cause was considered a competing risk for disease progression, and disease progression or death with persistent disease were considered competing risks for TRM. 23 Cox's proportional hazards regression analysis was used to evaluate predictors of OS on univariate analysis. Classification and regression tree (CART) analysis was used to evaluate predictors of OS on multivariate analysis to account for potential interaction effects. Predictors of disease progression and TRM were evaluated on univariate and multivariate analysis using competing risks regression analysis according to the method of Fine and Gray. 23 Variables of interest were age, HCT-CI, serum ferritin level at HSCT, donor type and hematopoietic stem cell source. We also focused on analyzing the impact of disease characteristics included in IPSS-R risk scoring. Cytogenetics, bone marrow blast count, hemoglobin, and platelet levels in addition to absolute neutrophil count (ANC) at HSCT were analyzed separately to observe their individual effects on disease outcome. Statistical significance was define at the 0.05 levels. Statistical analyses were performed using STATA 14.0 (StataCorp, College Station, TX).
RESULTS
Older MDS Patients Transplanted With RIC HSCT Have High-Risk Features
Patient and disease characteristics are provided in Table 1 . The median age at HSCT was 65 years (range, 60-77 years), and of 88 patients, 47 (53.4%) were > 65 years of age. Only 7 patients were 70 years of age. The study cohort had high-risk features; 30 of 88 (34%) patients had therapy-related MDS, 33 (38%) had histological subtypes of RAEB-1 and RAEB-2 at diagnosis, and 45 (51%) had an HCT-CI of 3. Cytogenetics findings were evaluable in 82 patients and were consistent with the poor/very poor risk group according to IPSS-R in 36 (40.1%) patients and monosomal karyotype (MKpos) in 24 (27.3%) patients. All 24 MKpos patients were in the poor/very poor risk group according to IPSS-R. The median bone marrow blast count at HSCT was 3% (range, 0%-13%). The hemoglobin level at HSCT was 10 g/dL in 39 (44.3%) patients, > 8 to < 10 g/dL in 19 (21.6%) patients, and 8 g/dL in 30 (34.1%) patients. The absolute neutrophil count at HSCT was 0. The serum ferritin level at HSCT, evaluable in 87 patients, was > 1000 mg/L in 40 (46%) patients. The median time from MDS diagnosis to transplantation was 9 months (range, 3-63 months). Of 88 patients, 57 (64.8%) and 72 (81.8%) patients had HSCT within 1 and 2 years after diagnosis, respectively. Of 88 patients, 77 (87.5%) had treatment for MDS before HSCT, and 11 were untreated. The most common MDS treatment was hypomethylating agents observed in 76 (86.4%) patients; 11 of 76 (14.5%) also received chemotherapy for MDS before HSCT. Posttransplantation maintenance therapy was given to 7 of 88 (7.9%) patients, and all 7 received 5-azacytidine 32 mg/m 2 subcutaneously for 5 consecutive days every 28 days. The administration of posttransplantation maintenance was based on physician preference. The sample size was too small for further analyses, but 3 of 7 patients had MKpos and the other 4 had cytogenetics abnormalities consistent with MKneg.
TRM Is the Major Reason for Failure After HSCT in Older MDS
The median follow-up of 36 survivors was 32 months (range, 6-98 months).
The incidence of grade 2-4 and grade 3-4 acute GVHD at day 180 was 43% (95% confidence interval [CI], 34%-55%) and 11% (95% CI, 6%-20%) respectively. The incidence of chronic GVHD at 3 years was 38% (95% CI, 29%-51%).
The TRM at day 100 and 3 years were 14% (95% CI, 8%-23%) and 35% (95% CI, 26%-47%), respectively. The cumulative incidence of progression at 3 years was 26% (95% CI, 18%-37%), and the estimate of OS was 41% (95% CI, 30%-52%).
The primary causes of death were progression of disease in 20 (38.5%) patients, acute GVHD in 6 (11.6%) patients, chronic GVHD in 7 (13.5%) patients, infection in 8 (15.4%) patients, and other reasons in 11 (21%) patients.
MKpos Patients Represent the Group With the Highest Risk of Progression After HSCT
Poor risk cytogenetics by IPSS-R and MK was the only prognostic factor for the disease progression by univariate analysis ( Table 2 ). Using IPSS-R, the risk of progression was highest in the poor/very poor cytogenetic risk group compared with the good/very good risk group (hazard ratio [HR], 7.7; 95% CI, 1.8-32; P 5 .005).
Similarly, patients with MKpos had a higher incidence of progression compared with good-risk cytogenetics (HR, 9.5; 95% CI, 2.2-41; P 5 .003) and with MKneg (HR, 3.3; 95% CI, 1.3-8.6; P 5 .01). There was no significant difference between MKneg and good-risk cytogenetic patients for risk of disease progression (HR, 2.8; 95% CI, 0.6-13; P 5 .2). The 3-year incidence of progression was 50% (95% CI, 11%-37%) for MKpos, 21% (95% CI, 10%-43%) for MKneg, and 7% (95% CI, 2%-28%) for good-risk cytogenetics as presented in Figure 1 . None of the other variables, including age >65 years and bone marrow blast count at HSCT, was found to have prognostic impact on disease progression.
HCT-CI 3 Was Associated With Higher TRM
Univariate analyses revealed that patients with platelet count <50 3 10 9 /L at HSCT (HR, 2.1; 95% CI, 0.9-4.8; P 5 .07) and HCT-CI 3 had higher 3-year TRM (HR, 3.1; 95% CI, 1.4-6.9; P 5 .007). As shown in Figure 2 , 3-year TRM was 49% if HCT-CI was 3 and 20% if HCT-CI was < 3. Older age, donor type, hematopoietic stem cell source, and higher ferritin levels were not prognostic for TRM.
When multivariate analysis was performed using statistically significant variables, HCT-CI 3 was confirmed to be the only independent prognostic factor for TRM at 3 years (HR, 3.1; 95% CI, 1.4-6.9; P 5 .007).
MK and HCT-CI Enable Definition of Prognostic Groups for OS
OS at 3 years was significantly decreased for patients with poor risk cytogenetics. Patients with poor/very poor risk group cytogenetics by IPSS-R had decreased survival compared with good/very good risk group patients (HR, 4.4; 95% CI, 1.9-10; P 5 .001). Similarly, MKpos and MKneg patients had worse outcomes when compared Figure 1 . MKpos patients had the highest incidence of disease progression, with 50% at 3 years. MKneg and good-risk cytogenetics were associated with less relapse incidence, with 21% and 7% at 3 years, respectively.
with good-risk cytogenetics (MKpos: HR, 4.3; 95% CI, 1.8-10.4; P 5 .001; MKneg: HR, 3.3; 95% CI, 1.4-7.9; P 5 .007). No significant difference was observed for OS between MKpos and MKneg patients (P 5 .4).
In addition to poor risk cytogenetics, higher serum ferritin level at HSCT (>1000 mg/L) (HR, 1.9; 95% CI, 1.1-3.5; P 5 .02), and HCT-CI3 were associated with inferior OS (HR, 1.9; 95% CI, 1.1-3.6; P 5 .02) as shown in Table 2 . Blast count at HSCT and age >65 years were associated with worse survival, but those characteristics did not reach statistical significance.
CART analyses were performed for the multivariate analyses of OS considering the interactions between the variables found to be prognostic for OS by univariate analyses. There was a significant interaction between cytogenetics and HCT-CI, indicating that the impact of HCT-CI was not uniform in different cytogenetic groups as shown in Figure 3 . In patients with MKpos, no survival difference at 3 years was observed between patients with HCT-CI 3 (17%; 95% CI, 3%-39%) and HCT-CI < 3 (17%; 95% CI, 9%-51%) (HR, 0.7; P 5 .5). Similarly, comparable survival outcomes were observed for MKneg patients with HCT-CI 3 (31%; 95% CI, 11%-54%) and HCT-CI < 3 (37%; 95% CI, 12%-62%) (HR, 1.3; P 5 .6). However, HCT-CI 3 was significantly associated with inferior OS compared with HCT-CI < 3 in good-risk cytogenetic patients. Three-year OS was 49% (95% CI, 19%-73%) if HCT-CI was 3 and 92% ((95% CI, 59%-99%) if HCT-CI was <3 (HR, 11.3; P 5 .03).
CART for multivariate analyses enabled us to take the significant interaction between cytogenetics and HCT-CI for OS into account and to identify the good- risk cytogenetic patients with HCT<3 as the best prognostic group for OS after allo-HSCT, as shown in Figure  4 . Our analyses showed that the worst OS was observed in MKpos patients independent of their HCT-CI, but the difference between the MKpos and other prognostic groups (other than good risk with HCT-CI 3) did not reach statistical significance.
DISCUSSION
We studied the outcomes of allogeneic HSCT using RIC regimens in older MDS patients aged 60 years and showed that long-term survival could be achieved, with a 3-year estimate of 41%. This result is quite encouraging considering the high-risk profile of our study cohort with a median age of 65 years, frequency of HCT-CI 3 in half of the patients, and cytogenetic abnormalities consistent with MKpos in 24% of the patients. The main observations were that 1) high-risk cytogenetics defined as MKpos was the only prognostic factor for higher risk of disease progression, 2) HCT-CI but not age at HSCT was prognostic for worse TRM, and 3) consequently, OS was determined by cytogenetics and HCT-CI.
Data are limited on HSCT with RIC regimens, a potentially curative therapy, in patients 60 years of age. The only available data published by a registry reported outcomes not only in older MDS patients but also in AML patients who received transplants with myeloablative and RIC regimens. The median age of those study cohorts were much younger (mostly in the mid-50s), and the reported transplantations were performed before Figure 4 . Classification and regression tree (CART) was used for the multivariate analyses to investigate independent prognostic variables for overall survival (OS). CART enabled us to take into account the interaction between cytogenetics and hematopoietic cell transplantation-comorbidity index (HCT-CI) for OS and revealed the good-risk cytogenetics with HCT-CI < 3 as the best prognostic group for OS with 3-year estimate of 92%.
2006
. 9, 10, 24 The Japan Society for HCT was the only registry study reporting older MDS patients who received transplants more recently, until 2010, but again with both myeloablative and RIC in a cohort of patients with median age <60 years. 25 Considering the concerns of increased risk of relapse with RIC regimens and worse outcome expectations in older patients with hematological malignances, disease-specific data in this group is important to help transplant physicians determine their treatment decision. Our study cohort including only MDS patients aged 60 years and transplanted with reduced intensity conditioning after 2005 revealed a 3-year progression incidence of 26%, which is lower compared with published reports. These findings suggest that older MDS patients may enjoy lower relapse incidence despite the use of RIC for allo-HSCT.
In our study, MKpos was the only poor prognostic factor for the incidence of disease progression. MKpos patients had 50% 3-year progression incidence in contrast to 7% in patients with good-risk cytogenetics defined as normal karyotype or other abnormalities, including isolated del(5q), del(12p), and del(20q). MKneg patients represented intermediate risk group with 21% 3-year progression incidence. These results are consistent with published data showing a higher relapse incidence in MDS patients with MKpos. [26] [27] [28] In a much younger MDS cohort transplanted with both RIC and MAC regimens, we previously had reported similar results with 3-year progression incidence of 60.9% in patients with MKpos and 16.9% with normal cytogenetic after allo-HSCT. 26 We believe that this high-risk group should be the target population for innovating transplantation strategies aimed to reduce the risk of progression. One approach might be using more intense conditioning regimens if the patient is medically fit. A recent BMT CTN phase 3 randomized clinical trial showing significantly improved relapse incidence in AML patients if transplanted with MAC regimens versus RIC supported this notion. 29 Our group also reported that HSCT with MAC using pharmacokinetics to target an average daily systemic exposure dose in a timed sequential approach allowed even older patients to tolerate more intensive regimen without increased regimen-related toxicity, 30, 31 and long-term results are awaited. Another interesting observation in our study was that blast count at HSCT did not have any impact on disease progression incidence after HSCT. However, one should be cautious while interpreting those results, given that the median blast count at HSCT was only 3% in our cohort.
Consistent with the literature, we showed that HCT-CI 3 was significantly associated with higher TRM in older MDS patients who received transplants with RIC, whereas older age had no effect. 32, 33 TRM at 3 years was 49% in patients with HCT-CI 3 even with the use of RIC regimens compared with 20% in patients with HCT-CI < 3. On the other hand, when the risk of transplant failure due to relapse risk was higher than that of TRM, as in patients with high-risk cytogenetics, we did not observe a decrease in the OS expectancy. It was only in the group of good-risk cytogenetics that HCT-CI identified different prognostic groups for survival. Despite this observation, we are certain that HCT-CI is an important prognostic factor that needs to be taken into account when finalizing the decision to proceed with SCT in older MDS patients. Because aging is a heterogeneous process that not only involves physiological changes but also has social, cognitive, and psychiatric components, one might assume novel assessment tools developed by geriatricians can be more helpful to assess the impact of aging on transplant outcomes. 34 Recently, the Comprehensive Geriatric Assessment (CGA), 35 one of many such tools to identify vulnerability, was investigated in older MDS patients, and the results demonstrated that CGA could uncover significant disability that was not identified by traditional evaluation measures. 36, 37 We believe that integration of geriatric assessment tools may lead to better identification of high-risk older patients for TRM and help guide treatment decisions.
In our study, no variable other than HCT-CIincluding higher ferritin levels at HSCT reflecting transfusion iron overload and use of matched unrelated/haploidentical donors-was found to be an independent prognostic factor for TRM. Registry and few single institution data have shown that the use of unrelated donors and mismatched donors was associated with higher risk of TRM in MDS patients after allogeneic HSCT compared with matched related donors. 10, 24, 33 The absence of such effect in our cohort can be explained by including only the HLA-A, HLA-B, HLA-C, and -DRB1 (by high-resolution molecular testing) matched unrelated donor recipients. Haploidentical donors were small in number, but all were treated with posttransplantation cyclophosphamide reported to improve outcomes. 38, 39 Our small group of 10 haploidentical transplant patients did not have inferior outcomes compared with matched sibling and unrelated donors. However, the role of haploidentical HSCT in older MDS patients needs to be investigated further in larger cohorts before its use is confirmed as safe and effective in patients without a matched related or unrelated donor available.
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